$92.00
The gold-standard GH secretagogue stack in a single vial — CJC-1295 No DAC (GHRH agonist) plus Ipamorelin (GHRP) work at two separate receptor sites to produce synergistic GH release that neither peptide achieves alone. One injection. Dual mechanism.
3-5 business days
SSL encrypted
Growth hormone release requires two signals: a GHRH signal (the “go”) and a GHRP signal (which amplifies the pulse and suppresses somatostatin, the inhibitory brake). CJC-1295 No DAC provides the GHRH signal at the pituitary level. Ipamorelin — a selective GHRP — amplifies the resulting pulse and suppresses somatostatin without the cortisol or prolactin elevation seen with older GHRPs. Together in a single injection, they produce GH pulses 3–5x higher than either compound alone. This is the combination that most research protocols are built around.
For women, this stack is compelling because female GH secretion is naturally higher amplitude but shorter duration than male GH — meaning the pulsatile mechanism that CJC/Ipamorelin leverages is already primed to respond. Women on this stack consistently report improvements in body composition (particularly visceral fat), deep sleep architecture, skin density, and recovery from training. The selective profile of Ipamorelin — no meaningful cortisol elevation — is particularly important for women, whose stress axis tends to be more reactive.
Female-calibrated dosing: 100–150mcg of the blend (equating to 50–75mcg each of CJC and Ipamorelin) subcutaneously at bedtime, 5 days/week. Women typically respond at the lower end. This is the ideal first GH secretagogue protocol. Run 8–12 weeks. Fast for 90 minutes before injection for best results.
Storage: Store lyophilized powder below -20°C. After reconstitution, refrigerate at 2–8°C and use within 30 days.
| Dosage | 10mg |
|---|---|
| Format | Injectable Blend |
| Cycle Length | 8–12 weeks |
| Storage | Freeze until use. Refrigerate after reconstitution. Use within 30 days. |
Reviews
There are no reviews yet.